| Title |
Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches
|
|---|---|
| Published in |
BioDrugs, May 2017
|
| DOI | 10.1007/s40259-017-0225-6 |
| Pubmed ID | |
| Authors |
Emilie Cayssials, Francois Guilhot |
| Abstract |
Imatinib has revolutionized the treatment and prognosis of chronic myeloid leukemia (CML) with survival rates now approaching those of the age-matched healthy population. To be able to discontinue tyrosine kinase inhibitor (TKI) treatment, it is necessary to develop complementary therapies to target minimal residual disease. Recent findings by a number of investigators in both CML mouse models and CML patients offer evidence that many factors in the leukemic microenvironment can collectively contribute to immune escape, including expansion of myeloid-derived suppressor cells, programmed death-1/programmed death-1 ligand interactions resulting in T-cell impairment, expression of soluble suppressive factors such as soluble CD25, and down-regulation of MHC molecules by CML cells. Other investigators have studied the role of cytokines on the resistance to TKIs by leukemic stem cells (LSCs) and have highlighted the implication of the JAK/STAT pathway as well as the interleukin 1 (IL-1) signaling pathway. Distinct immunologic strategies have been considered to harness the immune system or trigger LSC death to allow more CML patients to discontinue TKI treatment (so-called functional cure). Successful immunotherapy and TKI combination and the optimal timing of immunotherapy determination represent major challenges for the future. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 14% |
| Student > Ph. D. Student | 3 | 10% |
| Lecturer | 2 | 7% |
| Student > Doctoral Student | 2 | 7% |
| Researcher | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 14 | 48% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 21% |
| Biochemistry, Genetics and Molecular Biology | 4 | 14% |
| Agricultural and Biological Sciences | 2 | 7% |
| Immunology and Microbiology | 2 | 7% |
| Nursing and Health Professions | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 13 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2017.
All research outputs
#17,892,691
of 22,971,207 outputs
Outputs from BioDrugs
#568
of 660 outputs
Outputs of similar age
#221,470
of 309,527 outputs
Outputs of similar age from BioDrugs
#12
of 13 outputs
Altmetric has tracked 22,971,207 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 660 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 309,527 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.